Josias Pontes is the Chief Financial Officer of Sigilon Therapeutics, Inc., where he helped prepare the company for its IPO in 2020, which raised roughly $145 million. Most recently, Mr. Pontes was involved in the merger and acquisition process that resulted in Eli Lilly’s acquisition of Sigilon for up to $310 million. Before joining Sigilon, Mr. Pontes held the position of Senior Director, Financial Planning and Analysis at Zafgen, Inc., a biotechnology company, from December 2017 to August 2019. Mr. Pontes held the position of Senior Director of Finance at Juniper Pharmaceuticals, Inc. from 2016 to 2018. Mr. Pontes also worked in various finance roles of increasing responsibility at Genzyme, most recently serving as the Senior Director of Finance for the Rare Diseases business unit with 8 different commercial drugs. At Genzyme, he spent over a decade in different positions, leading the finance function to support the significant and rapid growth of the rare diseases business in Latin America and in the U.S. Mr. Pontes had multiple roles at Genzyme, working as Head of Finance and Controller at a country level in Brazil, Chile and Venezuela as well as at a regional level as Senior Director of Finance, Regional Controller Latin America. He has also held progressive finance positions in other companies, in manufacturing and commercial settings of different industries such as air conditioning and automotive. Mr. Pontes began his accounting career at a United Steel Corporation subsidiary at the age of 15 and had approximately 8 years of accounting experience when he joined Price Waterhouse (now PricewaterhouseCoopers). He obtained his CPA designation in São Paulo, Brazil. He has an MBA from Ohio University and a B.A. in Accounting from FECAP University in Sao Paulo, Brazil.
Former Chief Financial Officer, Sigilon Therapeutics